指南与共识儿科与产科急症重症综合管理与镇静镇痛

调查显示早产儿动脉导管未闭的诊断和治疗缺乏共识

Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity.
指南 / 共识 · Eur J Pediatr · 2022-03-19
一句话结论国际调查显示早产儿PDA缺乏( inter)national指南,筛查、诊断标准与治疗策略高度异质,现有证据不足以统一临床实践。

该研究为2019年9月至2020年3月开展的国际互联网调查,共发送144份问卷,71/144(49%)可分析,其中56/71(79%)完整填写。受访者主要为III级NICU的新生儿医师,36/71(51%)曾(合)著PDA论文。调查涵盖指南可获得性、筛查策略、血流动力学显著性的诊断标准、治疗策略及疗效指标,并设置10条临床均势声明(Likert量表)。结果显示缺乏国家指南,筛查、诊断标准、治疗策略和效果评估高度异质;是否发表PDA论文的受访者间无重大显著差异;筛查PDA者在需要筛查、早期积极治疗上得分显著更高;所有临床均势声明得分差异很大。结论认为当前证据不够稳健,不足以将治疗策略统一为( inter)national指南。

要点

  • 71/144(49%)可分析问卷中,56/71(79%)完整填写,受访者主要为III级NICU新生儿医师。
  • 调查显示缺乏国家指南,筛查策略、血流动力学显著性诊断标准、治疗策略及效果评估高度异质。
  • 是否(合)著PDA论文的受访者之间无重大显著差异。
  • 筛查PDA的受访者在需要筛查、早期积极治疗上得分显著更高。
  • 所有临床均势声明得分差异很大,现有证据不足以统一为( inter)national指南。

适用人群与场景

  • 国际互联网调查的受访者,主要为III级新生儿重症监护病房的新生儿医师,其中36/71(51%)曾(合)著PDA论文。

研究设计与关键结果

  • 研究类型为国际互联网调查,2019年9月至2020年3月进行,共发送144份问卷,71/144(49%)可分析,56/71(79%)完整填写。
  • 调查收集基线特征、指南可获得性、PDA筛查策略、血流动力学显著性的诊断标准、治疗策略及疗效指标,并设置10条临床均势声明(Likert量表)。
  • 结果显示缺乏国家指南,筛查策略、诊断标准、治疗策略和效果评估高度异质。
  • 是否(合)著PDA论文的受访者之间无重大显著差异。
  • 筛查PDA的受访者在需要筛查、早期积极治疗上得分显著更高。
  • 所有临床均势声明得分差异很大。

证据类型、等级与局限

  • 证据类型:国际互联网调查。
  • 作者结论:当前证据不够稳健,不足以将治疗策略统一为( inter)national指南。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 调查显示缺乏国家指南,筛查策略、诊断标准、治疗策略和效果评估高度异质,当前实践不统一。
  • 作者认为当前证据不够稳健,不足以将治疗策略统一为( inter)national指南。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

To gain insight in the availability of guidelines, diagnostic criteria, and treatment strategies and whether clinical equipoise regarding optimal treatment for patent ductus arteriosus (PDA) in prematurity is present. We hypothesized that (co-)authors of PDA-related papers were more likely to screen for a PDA and would treat earlier and more aggressively. An international internet-based survey between September 2019 and March 2020 in which we collected (1) baseline characteristics; (2) availability of guidelines; (3) screening strategy for PDA; (4) diagnostic criteria for hemodynamic significance; (5) treatment strategy; and (6) metrics of treatment efficacy. Finally, ten clinical equipoise statements were posed on a Likert scale. In total, 144 surveys were sent, of which 71/144 (49%) surveys could be analyzed with 56/71 (79%) fully completed surveys. The respondents, mainly neonatologists in a level III neonatal intensive care unit, of whom 36/71 (51%) had (co-)authored a publication on the PDA, highlighted a lack of national guidelines, heterogeneous approach to screening strategies, and marked variability in diagnostic criteria to assess hemodynamic significance, treatment strategies and effect measurement. No major significant differences were observed between respondents who did or did not (co-)author a publication on the PDA. Respondents who screened for PDA scored significantly higher on the need for screening, early and aggressive treatment. Remarkably, the scores of all statements regarding clinical equipoise varied widely. Conclusions: Our survey highlights the lack of guidelines and enormous heterogeneity in current practice. Current evidence is not robust enough to harmonize current treatment strategies into (inter)national guidelines. What is Known: • Patent ductus arteriosus (PDA) incidence is inversely related to gestational age. • Although early pharmacological treatment induces PDA closure, optimal treatment is debated due to the lack of beneficial effects on outcome. What is New: • In the absence of (inter)national guidelines, diagnostic and treatment strategies are heterogeneous and contradictory, even in a selected hemodynamically- interested group. • Different PDA screening strategies did, while PDA publication status did not, show significant differences in treatment strategy and responses to equipoise statements.

来源:Eur J Pediatr,查看原文。版权归原作者所有。

参考来源

  1. Hundscheid T, El-Khuffash A, McNamara PJ, et al. Survey highlighting the lack of consensus on diagnosis and treatment of patent ductus arteriosus in prematurity. Eur J Pediatr. 2022. PMID: 35305143. doi:10.1007/s00431-022-04441-8

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。